Drug Profile


Alternative Names: CC-5013; CDC-501; CDC-5013; ENMD-0997; IMiD-3; Ladevina; Revimid™; Revlimid

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator Celgene Corporation
  • Developer Celgene Corporation; Dana-Farber Cancer Institute; H. Lee Moffitt Cancer Center and Research Institute; Indiana University School of Medicine; IRCCS San Raffaele; National Cancer Institute (USA); National Heart, Lung and Blood Institute; Roche; Roswell Park Cancer Institute; SCRI Development Innovations; University of Florida; Washington University School of Medicine
  • Class 2 ring heterocyclic compounds; Antineoplastics; Imides; Isoindoles; Piperidones; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Immunomodulators; Interleukin 1 beta inhibitors; Interleukin 10 stimulants; Interleukin 2 receptor modulators; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Myelodysplastic syndromes; Chronic lymphocytic leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mantle-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes
  • Preregistration Adult T-cell leukaemia-lymphoma
  • Phase III Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Prostate cancer
  • Phase II Acute myeloid leukaemia; Histiocytosis; Hodgkin's disease
  • Phase I Cancer; Chronic myeloid leukaemia; Peripheral T-cell lymphoma
  • No development reported Eye neoplasms; Glioblastoma; Myelofibrosis
  • Discontinued Colorectal cancer; Heart failure; Hepatocellular carcinoma; Inflammation; Malignant melanoma

Most Recent Events

  • 08 Feb 2017 Preregistration for Adult T-cell leukaemia-lymphoma in Japan (PO) before February 2017 (Celgene pipeline, February 2017)
  • 27 Jan 2017 The CHMP of the European Medicines Agency recommends positive opinion of lenalidomide (Maintenance therapy, Newly diagnosed, Monotherapy) for Multiple myeloma in European Union
  • 26 Jan 2017 Celgene completes enrolment in its phase III AUGMENT trial for Non-Hodgkin's lymphoma (Second-line therapy or greater, Combination therapy) in Belgium, Brazil, China, the Czech Republic, France, Germany, Israel, Italy, Poland, Portugal, Russia, Spain, Turkey, United Kingdom and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top